Seung Tae Tae Lee MD Ph.D.

Oncology•Baltimore, MD

Hematologic Oncology

Clinical Fellow

Request appointment

22 S Greene StBaltimore, MD 21201
Book by Phone+1(443) 241-8845

Overview of Dr. Lee

Dr. Seung Tae Lee is an oncologist in Baltimore, MD and is affiliated with University of Maryland Medical Center. He received his medical degree from Yonsei University College of Medicine and has been in practice 36 years. He is one of 111 doctors at University of Maryland Medical Center who specialize in Oncology. He also speaks multiple languages, including Korean. He has more than 90 publications and over 500 citings.

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Montefiore - Mount Vernon HospitalResidency, Internal Medicine, 2009 - 2012
Yonsei University College of MedicineClass of 1990

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

MD State Medical License 2015 - 2028
TX State Medical License 2012 - 2016
MA State Medical License 2011 - 2012
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2020 Sep 03
ACTIVE_NOT_RECRUITING
PHASE2, PHASE3
Roles: Principal Investigator, Contact

Publications & Presentations

PubMed

Comprehensive Assessment of CD19 Immunohistochemical Staining in Classic Hodgkin Lymphoma.
Sarah R Helman, Fikru Merechi, Hanan Alharthy, Rima Koka, Seung Tae Lee
The American Journal of Surgical Pathology. 2026-05-01
4 citations
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study.
Carrie Thompson, Marek Trněný, Franck Morschhauser, Gilles Salles, Patrick M Reagan
Blood. 2026-01-15
2 citations
A multicenter phase 1/2 trial of lenalidomide and dose-adjusted EPOCH-R in MYC-associated DLBCL.
Kirk Cahill, James Godfrey, Chadi Nabhan, Justin Kline, Peter A Riedell
Blood Advances. 2025-11-11

Abstracts/Posters

A Phase I Study Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Seung Tae Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Increased Cortical Glycolysis Following CD19 CART Therapy: A Radiographic Surrogate for an Altered Blood-Brain Barrier
Seung Tae Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...
Seung Tae Lee, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019